CSL Subsidiary Donates von Willebrand Factor / Factor VIII to World Federation of Hemophilia
Company gives more than 1 million units of VWD medication via WFH’s Global Alliance for Progress program as part of its 3-year commitment to the organization
King of Prussia, PA, and Montreal, Canada — 18/07/2011
CSL Behring has donated more than 1 million international units (IU) of von Willebrand factor (VWF)/Factor VIII (FVIII) replacement medication to patients through the World Federation of Hemophilia (WFH). The donation supports WFH’s progress in improving the diagnosis and treatment of bleeding disorders in developing countries through its Global Alliance for Progress (GAP) program. It is part of the commitment CSL Behring has made to WFH to donate two million IUs of FVIII each year for three years. Today’s donation is commercially valued at $1.3 million.
CSL Behring, as a member of the CSL Group, is committed to contributing to the economic, social and environmental well-being of its communities.
Read the entire CSL Behring Press Release